RE: SP - thoughts22 Apr 2021 14:49
Please excuse the copy/paste DonaldTrumpsWig, but your post is epic:
Company with fantastic IP in cancer therapies pivots to meet unexpected and unprecedented demand for CV test.
From standing start, during a pandemic, delivers world class LFT whilst navigating inevitable delays, wrong choice of partners, regulatory hurdles, changes in sample collection methods etc etc
Whilst all this is going on, maintaining cancer pipeline and signing license agreements with numerous partners all of whom irrevocably endorse the IP of affimers
Today the CEO confirms all of the above, stating that demand is almost unlimited and the remaining hurdle is simply production capacity.
Two choices for shareholders:
Choice one, recognise that this is a unicorn investment opportunity, turn off you phone, enjoy the sunshine safe in the knowledge that the SP will take care of itself.
Choice two, refresh this BB and the SP every two minutes thus letting Nd and the other bedwetters get inside your head by overanalysing every nuance.
This is the investment opportunity of a generation, nothing said today has diminished that. The final hurdle for me was CV and that was cleared with ease. Find a beer garden and enjoy.